Can apoptosis in benign proliferative lesions predict risk of cancer development?

Medical Hypotheses

Volumn 50, Issue 1, 1998, Pages 49-53

  Snyder, R D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CANCER; CANCER RESEARCH; CANCER RISK; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; HUMAN; HYPOTHESIS; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY;

GOES;

EID: 0031964026     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(98)90177-3     Document Type: Article

References (40)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-25.
2. Nowell P C. Mechanisms of tumor progression. Cancer Res 1986; 46: 2203-2207.
3. Heddle J A, Krepinsky A P, Marshall R R. Cellular sensitivity to mutagens and carcinogens in the chromosome-breakage and other cancer-prone syndromes. In: German J, ed. Chromosome Mutation and Neoplasia. New York: Liss, 1983: 203-234.
4. Kraemer K H, Lee M M, Scotto J. DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum. Carcinogenesis 1984; 5: 511-514.
5. Swift M, Reitnauer P J, Morrell D, Chase C L. Breast and other cancers in families with ataxia telangiectasia. N Engl J Med 1987; 316: 1289-1294.
6. Li F P, Fraumeni J F Jr, Mulvihill J J et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48: 5358-5362.
7. Pandita T K, Hittelman W. Evidence of a chromatin basis for increased mutagen sensitivity associated with multiple primary malignancies of the head and neck. Intl J Cancer 1995; 61: 738-743.
8. Schantz S P, Spitz M, Hsu T C. Mutagen sensitivity in patients with head and neck cancers: a biological marker for risk of multiple primary malignancies. J Natl Cancer Inst 1990; 82: 1773-1775.
9. Hsu T C. Genetic predisposition to cancer with special reference to mutagen sensitivity. In Vitro 1987; 23: 591-603.
10. Grossman L, Wei Q. DNA repair capacity (DRC) as a biomarker of human variational responses to the environment. In: Vos J-MH, ed. DNA Repair Mechanisms: Impact on Human Diseases and Cancer. New York: Landes, 1994: 329-347.
11. Hagmar L, Brogger A, Hansteen I-L et al. Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res 1994; 54: 2919-2922.
12. Coleman W B, Tsongalis G J. Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation. Clin Chem 1995; 41(5): 644-657.
13. Tainsky M A, Bischoff F Z, Strong L C. Genomic instability due to germline p53 mutations drives preneoplastic progression toward cancer in human cells. Cancer Metastasis Rev 1995; 14: 43-48.
14. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992; 89: 4495-4499.
15. Lowe S, Schmitt E, Smith S, Osborne B, Jacks T. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
16. Wright S C, Zhong J, Larrick J W. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 1994; 8: 654-660.
17. Gerbracht U, Bursch W, Kraus P. Effects of hypolipidaemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver. Carcinogenesis (Lond) 1990; 11: 617-624.
18. Snyder R D, Pullman J, Carter J H, Carter H W, DeAngelo A B. In vivo administration of dichloroacetic acid suppresses spontaneous apoptosis in murine hepatocytes. Cancer Res 1995; 55: 3702-3705.
19. Ledda-Columbano G M, Columbano A. Apoptosis and hepatocarcinogenesis. In: Tomei D L, Cope F O, eds. Apoptosis: the Molecular Basis of Cell Death. Cold Spring Harbor Laboratory Press, 1991: 101-119.
20. Budtz P E. Epidermal homeostasis: a new model that includes apoptosis. In: Tomei D L, Cope F O, eds. Apoptosis II: The Molecular Basis of Apoptosis in Disease. Cold Spring Harbor Laboratory Press, 1994: 165-183.
21. Kuerbitz S, Plunkett B, Walsh W. Wildtype p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89: 7491-7495.
22. Hickman J A. Apoptosis induced by anticancer drugs. Cancer Metast Rev 1992; 11: 121-139.
23. Barry M A, Behnke C A, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990; 40: 2353-2362.
24. Hartwell L H, Weinert T A. Checkpoints: controls that ensure the order of cell cycle events. Science 1989; 246: 629-634.
25. Gavrielli Y, Sherman Y, Ben-Sasson S A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 19: 493-501.
26. Lipponen P, Aaltomaa S, Kosma V-M, Syrjanen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994; 14: 2068-2073.
27. Gaffney E F. The extent of apoptosis in different types of high grade prostatic carcinoma. Histopathology 1994; 25: 269-273.
28. Aihara M, Truong L D, Dunn J K, Wheeler T M, Scardino P T, Thompson T C. Frequency of apoptotic bodies positively correlates with gleason grade in prostate cancer. Hum Pathol 1994; 25: 797-801.
29. Vesalainen S, Lipponen P, Talja M, Syrjanen K. Histological grade, perineural infiltration, tumor-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994; 12: 1797-1803.
30. Tatebe S, Ishida M, Kasagi N, Tsujitani S, Kaibara N, Ito H. Apoptosis occurs more frequently in metastatic foci than in primary lesions of human colorectal carcinomas: analysis by terminal-deoxynucleotidyl-transferase-mediated dUTP-biotin nick end labeling. Int J Cancer 1996; 65: 173-177.
31. Shibata M-A, Maroulakou I G, Jorcyk C L, Gold L G, Ward J M, Green J E. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: Suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res 1996; 56: 2998-3003.
32. Tsujitani S, Shirai H, Tatebe S et al. Apoptotic cell death and its relationship to carcinogenesis in colorectal carcinoma. Cancer 1996; 77: 1711-1716.
33. Berges R R, Vukanovic J, Epstein J I et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995; 1: 473-480.
34. Levine E L, Renehan A, Gossiel R et al. Apoptosis, intrinsic radiosensitivity and prediction of radiotherapy response in cervical carcinoma. Radiother Oncol 1995; 37: 1-9.
35. Leoncini L, Vecchio M T D, Megha T et al. Correlation between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol 1993; 142: 755-763.
36. Aihara M, Scardino P T, Truong L D et al. The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinomas of the prostate. Cancer 1995; 75: 522-529.
37. Tormanen U, Eerola A-K, Rainio P et al. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res 1995; 55: 5595-5602.
38. Mooney E E, Peris JMR, O'Neill A, Sweeney E C. Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol 1995; 48: 242-244.
39. Snyder R D, Carter H W, Johnston J O et al. Evaluation of apoptosis in benign lesions of the breast and prostate as a possible predictor of cancer risk. Anticancer Res 1995; 15(5A): 1724.
40. Johnston J O, Snyder R D, Carter H W, Pullman J L, Carter J H. Use of archival tissues to evaluate proliferative and apoptotic indices in human prostate carcinoma and benign prostatic hyperplasia. 1996 International Symposium on Biology of Prostate Growth, Washington, DC.